| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7da9064f16bf42b16a1d6bdfb76d7a7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-90694 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M5-168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5308
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y107-03003 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M5-168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-49 |
| filingDate |
2010-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6d2be3f48b6ff6da42137e83754f3be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c73c99f0982c784ee731cb875c45d159 |
| publicationDate |
2012-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20120046125-A |
| titleOfInvention |
Methods and kits for monitoring serum uric acid during PEGylated freecase treatment to predict risk of infusion reaction and antibody-mediated loss of response |
| abstract |
The present invention provides methods and kits for predicting infusion reaction risk and antibody mediated loss of response during intravenous treatment of pegylated freecase in gout patients. Conventional SUA monitoring can be used to identify patients receiving pegylated freecases, which may no longer have a therapeutic effect and have a greater risk of infusion reactions. |
| priorityDate |
2009-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |